PORT WASHINGTON, N.Y., October 05, 2016 - Pall Corporation, a global leader in bioprocess equipment and disposables, announced the signing of a commercial collaboration agreement with RoosterBio Inc., an innovative adult stem cell technology company. The agreement will encompass a co-development and marketing partnership, delivering complete solutions for industrial-scale bioreactor expansion of human Mesenchymal Stem/Stromal Cells (hMSCs). These systems will enable the BioPharmaceutical industry to accelerate product development, reduce clinical translation timelines and ultimately streamline the commercialization pathway for stem cell-based therapies.

 

Pall Life Sciences has continued expanding their Cell Therapy Manufacturing solutions portfolio, and this partnership furthers that aim. The complementary tools that RoosterBio and Pall contribute address a major challenge and current bottleneck in the multi-billion dollar Regenerative Medicine industry. Stem cell-based technologies are progressing rapidly through the clinic, but manufacturing of cellular therapeutics, including hMSCs, is significantly limited in scale. There are few standards or complete solutions currently marketed that enable simple, rapid development of scalable production methods of hMSCs. The strategic alliance between Pall and RoosterBio will provide total bioprocess solutions for cell culture of low cost, translation-friendly hMSCs for development of Cell Therapy, Tissue Engineering, Drug Screening, and Regenerative Medicine products.

 

Mario Philips, president, single-use technologies, stated, “Our vision is aligned with the customer requirements of large scale stem cell culture. Along with the RoosterBio hMSCs and media, the Pall solution offerings such as XRS 20 and Xpansion multiplate bioreactors, SoloHill microcarriers, and Allegro biocontainers enable our customers to grow stem cells on an industrially relevant scale.”

 

Jon Rowley, RoosterBio’s Chief Executive & Technical Officer, states: “Our mission at RoosterBio is to greatly increase the availability and accessibility of stem cell technologies to researchers and product developers across the globe. We are excited to be working with Pall and their innovative technology team to develop complete solutions for the simple and affordable generation of industrial quantities of hMSCs. Pall’s global team will be critical in driving rapid adoption of these systems on an international scale. This partnership will have a major impact on the pace of the Regenerative Medicine field.”

 

About Pall Corporation

 

Pall Corporation is a filtration, separation and purification leader providing solutions to meet the critical fluid management needs of customers across the broad spectrum of life sciences and industrial manufacturing. Pall works with customers to advance health, safety and environmentally responsible technologies. The Company’s engineered products enable process and product innovation and minimize emissions and waste. Pall Corporation serves customers Worldwide. For more information, please visit: www.pall.com, or follow us on social media at: Facebook; Google+; LinkedIn; Twitter; and YouTube.

 

About RoosterBio

 

RoosterBio is a privately held biofabrication technology and products company focused on accelerating the development of a sustainable regenerative medicine industry, one customer at a time. RoosterBio has simplified and standardized how stem cells are purchased, expanded, and used in development, leading to marked time and costs savings for customers. RoosterBio’s innovative products are ushering in a new era of productivity and standardization into the field, where researchers spend newly found time and money performing more high-value experiments, accelerating the road to discovery in Regenerative Medicine. RoosterBio serves customers Worldwide. For more information, please visit www.roosterbio.com, or follow on twitter (@RoosterBio), or read the blog “Democratizing Cell Technologies” (www.roosterbio.blogspot.com).

For more information, please contact us at: info@roosterbio.com

View source version on businesswire.com: http://www.businesswire.com/news/home/20161005005744/en/

Pall Life Sciences
Rebecca Kale, Senior Product Marketing Manager
Rebecca_kale@pall.com

More Biotech Press Releases
Read all the latest news and developments from Pall and keep in touch with industry trends and opinion.
July 2019
July 16, 2019: Servier chooses Pall as exclusive technology and services provider for planned Bio-S biomanufacturing facility in France
April 2019
April 29, 2019: Freeline's (AAV) manufacturing platform and Pall’s iCELLis bioreactor system combine to achieve commercial-scale and high quality production of AAV gene therapy vectors
March 2019
March 19, 2019: New lab will serve as a dedicated platform where the industry can access shared resources including equipment, expertise and project work to find innovative solutions to manufacturing needs for biologic medicines, such as cell-based immunotherapies
March 13, 2019: Pall Biotech to distribute ARTeSYN’s standard hardware and liner components for fluid flow control. Customers to benefit from the flexibility, agility and reliability required for their bioprocessing journey, with accelerated implementation of robust and standardized single-use fluid management and control
March 11, 2019: Pall Biotech to integrate and distribute Broadley-James’ advanced single-use probe and flow cell pH sensors; sensor will be integrated into Pall Biotech’s single-use technologies
December 2018
December 18, 2018: New centre to give Pall customers options ranging from batch to single use and continuous bioprocessing solutions, and to provide technology solutions that meet current needs, while offering some of the most progressive technological solutions for the future
November 2018
November 26, 2018: Cobra and Pall to make commercialisation of gene therapies safer, faster, and cheaper than ever before, help increase patient access to gene therapy and further establish best practices in manufacturing
October 2018
October 2, 2018: New centre will work to enhance drug production and empower the future workforce, reinforcing Pall's commitment to continuously improve bioprocesses through strategic partnerships
September 2018
September 24, 2018: New collaboration to see G-CON PODs customized with Pall technologies, addressing customer demand for higher efficiencies, while enjoying more flexibility through scale-out and localization of manufacturing
September 11, 2018: Pall and Aetos partner to combine bioreactors, mixing and storage, and downstream technologies with cell lines and manufacturing processes for expedited biosimilars development